NEWS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
Sutro Biopharma Collaborates with Celgene Corporation to Design and Develop Next-Generation Antibody Drug Conjugates and Bispecific Antibodies
SAN FRANCISCO, Dec. 18, 2012 - Sutro Biopharma today announced a collaboration with Celgene Corporation to design and develop novel antibody drug conjugates (ADCs) and bispecific antibodies for two undisclosed targets and to manufacture a proprietary Celgene antibody....
Sutro Biopharma Expands Senior Management Team Jeremy Bender, Ph.D., Joins as Chief Business Officer; Aaron K. Sato, Ph.D., Named Vice President, Research
SAN FRANCISCO, October 24, 2012 - Sutro Biopharma, a biopharmaceutical company developing a new generation of antibody drug conjugate therapeutics and bifunctional antibody-based therapeutics for targeted cancer therapies, today announced the expansion of its senior...
Rapid Design and Manufacture of Single Species, Site-Specific ADCs using Cell-Free Synthesis with nnAAs
Hallam, Trevor, Rapid Design and Manufacture of Single Species, Site-Specific ADCs using Cell-Free Synthesis with nnAAs. Presented at the 3rd World ADC Summit, San Francisco (PDF) Read More
Sutro Closes $16.5 Million Second Tranche of Series C Financing
SAN FRANCISCO, May 8, 2012 - Sutro Biopharma today announced the closing of the $16.5 million second tranche of its Series C financing. This financing was led by Skyline Ventures and included participation of Lilly Ventures, Amgen Ventures, SV Life Sciences and Alta...
Aglycosylated Antibodies and Antibody Fragments Produced in a Scalable in Vitro Transcription-Translation System
Gang Yin, Eudean D. Garces, Junhao Yang, Juan Zhang, Cuong Tran, Alexander R. Steiner, Christine Roos, Sunil Bajad, Susan Hudak, Kalyani Penta, James Zawada, Sonia Pollitt and Christopher J. Murray, Aglycosylated antibodies and antibody fragments produced in a...
Sutro Announces Newly Formed Scientific Advisory Board Renowned Researchers James A. Wells, Ph.D., and James R. Swartz, Sc.D., to Guide Sutro’s Advancing Therapeutic Pipeline
SAN FRANCISCO, Jan. 7, 2012 - Sutro Biopharma, a biopharmaceutical company developing novel and biosuperior protein therapeutics with improved pharmaceutical properties, today announced that it has appointed James A. Wells, Ph.D., and James R. Swartz, Sc.D., to its...
Sutro Biopharma’s Trevor Hallam Offers a Glimpse into the Future of Drug Design
12/5/2011 - BioPharm International Podcast (3of3): Sutro Biopharma's Trevor Hallam offers a glimpse into the future of drug design By: Trevor J. Hallam
Sutro Biopharma’s Trevor Hallam Describes a Future cGMP Manufacturing Facility
BioPharm International Podcast (2of3): Sutro Biopharma's Trevor Hallam describes a future cGMP manufacturing facility By: Trevor J. Hallam
Sutro Biopharma and Cell-Free Protein Expression Systems
BioPharm International Podcast (1of3): Sutro Biopharma and Cell-Free Protein Expression Systems By: Trevor J. Hallam
Preparation and Testing of E. coli S30 In Vitro Transcription Translation Extracts
James F. Zawada, Preparation and Testing of E. coli S30 In Vitro Transcription Translation ExtractsRibosome Display and Related Technologies Methods in Molecular Biology Volume 805, 2012, pp 31-41 Date: 20 Oct 2011 Read More ...